Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5308245 | 1.00 | HTR2A (0.60) | HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL5473413 | 0.87 | TAAR1 (0.46) | HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL394374 | 0.85 | PTGS2 (0.55) | HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL20553334 | 0.85 | PTGS2 (0.55) | HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL394373 | 0.85 | PTGS2 (0.55) | HTR2AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL35210353 | 0.84 | PTGS2 (0.53) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL31545682 | 0.84 | PTGS2 (0.53) | HTR2AHTR2CHTR2B | |
| SCHEMBL29813314 | 0.82 | HTR2A (0.44) | HTR2ATAAR1 | |
| SCHEMBL5307529 | 0.81 | HSD17B10 (0.43) | HTR2A | |
| Hydrochloric Acid SCHEMBL29896441 | 0.81 | HTR2A (0.42) | HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12263155-B2 | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | REMEDI, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12239632-B2 | Asymmetric allyl tryptamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2025024400-A2 | SUBSTITUTED TRYPTAMINES AND USES THEREOF | 2A BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240285578-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240277665-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396162-A2 | ASYMMETRIC ALLYL TRYPTAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024028779-A1 | AMANITA MUSCARIA VAPORIZER FORMULATIONS AND DEVICES | PSYCHED WELLNESS LTD. (CA) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023034645-A2 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239632-B2 | Asymmetric allyl tryptamines | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 6/4885HTR2B 19/4885 |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | HTR2A 25/4885HTR2C 6/4885HTR2B 28/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885HTR2C 44/4885HTR2B 85/4885 |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 6/4885HTR2B 19/4885 |
| US-20240285578-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | HTR2A 9/4885HTR2C 11/4885HTR2B 16/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | HTR2A 4/4885HTR2C 15/4885HTR2B 25/4885 |
| US-12263155-B2 | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | MAOA, MAOB, HTR1A | HTR2A 9/4885HTR2C 11/4885HTR2B 16/4885 |
| US-20240277665-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 6/4885HTR2B 19/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885HTR2C 44/4885HTR2B 85/4885 |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | HTR2A 9/4885HTR2C 11/4885HTR2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.